Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Section Editors
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
HEPATOLOGY / CLINICAL RESEARCH
Metabolic insights into metabolic dysfunction-associated steatotic liver disease: the impact of gut microbiota and TCM constitutions
1
Preventive Treatment Department, Changzhou Traditional Chinese Medicine Hospital Affiliated to Nanjing University of Chinese Medicine, China
2
Department of Science and Education, Wujin Traditional Chinese Medicine Hospital, China
3
Department of Clinical Nutrition, Academy of Health and Rehabilitation, Academy of Acupuncture and Tuina, Nanjing University of Chinese Medicine, China
4
First Clinical Medical College, Nanjing University of Chinese Medicine, China
Submission date: 2025-06-03
Final revision date: 2025-08-02
Acceptance date: 2025-09-12
Online publication date: 2026-02-08
Corresponding author
Dongxue Lu
Department of Clinical Nutrition Academy of Health and Rehabilitation Academy of Acupuncture and Tuina Nanjing University of Chinese Medicine China
Department of Clinical Nutrition Academy of Health and Rehabilitation Academy of Acupuncture and Tuina Nanjing University of Chinese Medicine China
KEYWORDS
metabolic dysfunction-associated steatotic liver diseasetraditional Chinese medicine constitutiongut microbiota16S rRNA sequencingmetabolic pathwayspersonalized treatment
TOPICS
ABSTRACT
Introduction:
Metabolic dysfunction-associated steatotic liver disease (MASLD) is intricately linked to gut microbiota dysbiosis and has been associated with different traditional Chinese medicine (TCM) constitution types. This study explored the fecal microbiota composition in MASLD patients to investigate the associations underlying the disease.
Material and methods:
In this study, 51 MASLD patients and 46 healthy controls were classified into seven TCM constitution groups based on high-throughput sequencing of fecal samples. Analyses were conducted to compare microbial communities, metabolite profiles, and metabolic pathways among these constitution groups. The relationships between specific microbiota and biochemical indicators were evaluated using linear discriminant analysis (LDA) effect size (LEfSe) and Spearman correlation analyses.
Results:
MASLD patients exhibited reduced fecal microbiota diversity compared to healthy controls, with significant variations in microbial structure among TCM constitution groups. The damp-heat constitution (DHC) and phlegm-dampness constitution (PDC) groups displayed enriched populations of specific microbial species, distinct bacterial taxa, and unique metabolite profiles. Multiple significant pathways related to amino acid, fatty acid, and carbohydrate metabolism were identified through metabolic pathway enrichment analysis. Significant correlations were observed between specific microbial taxa and biochemical indicators such as triglycerides, total cholesterol, alanine aminotransferase (ALT), and aspartate aminotransferase (AST).
Conclusions:
This study highlights the close association between alterations in gut microbiota, TCM constitution differences, and MASLD progression. The findings suggest that changes in microbial diversity and metabolite profiles may contribute to MASLD pathogenesis. The identification of constitution-specific microbial may provide insights into personalized intervention strategies for MASLD.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is intricately linked to gut microbiota dysbiosis and has been associated with different traditional Chinese medicine (TCM) constitution types. This study explored the fecal microbiota composition in MASLD patients to investigate the associations underlying the disease.
Material and methods:
In this study, 51 MASLD patients and 46 healthy controls were classified into seven TCM constitution groups based on high-throughput sequencing of fecal samples. Analyses were conducted to compare microbial communities, metabolite profiles, and metabolic pathways among these constitution groups. The relationships between specific microbiota and biochemical indicators were evaluated using linear discriminant analysis (LDA) effect size (LEfSe) and Spearman correlation analyses.
Results:
MASLD patients exhibited reduced fecal microbiota diversity compared to healthy controls, with significant variations in microbial structure among TCM constitution groups. The damp-heat constitution (DHC) and phlegm-dampness constitution (PDC) groups displayed enriched populations of specific microbial species, distinct bacterial taxa, and unique metabolite profiles. Multiple significant pathways related to amino acid, fatty acid, and carbohydrate metabolism were identified through metabolic pathway enrichment analysis. Significant correlations were observed between specific microbial taxa and biochemical indicators such as triglycerides, total cholesterol, alanine aminotransferase (ALT), and aspartate aminotransferase (AST).
Conclusions:
This study highlights the close association between alterations in gut microbiota, TCM constitution differences, and MASLD progression. The findings suggest that changes in microbial diversity and metabolite profiles may contribute to MASLD pathogenesis. The identification of constitution-specific microbial may provide insights into personalized intervention strategies for MASLD.
REFERENCES (36)
1.
Gerges SH, Wahdan SA, Elsherbiny DA, El-Demerdash E. Non-alcoholic fatty liver disease: an overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions. Life Sci 2021; 271: 119220.
2.
Dou L, Shi X, He X, Gao Y. Macrophage phenotype and function in liver disorder. Front Immunol 2020; 10: 3112.
3.
Draijer L, Benninga M, Koot B. Pediatric NAFLD: an overview and recent developments in diagnostics and treatment. Expert Rev Gastroenterol Hepatol 2019; 13: 447-61.
4.
Powell EE, Wong VWS, Rinella M. Non-alcoholic fatty liver disease. Lancet 2021; 397: 2212-24.
5.
Govaere O, Petersen SK, Martinez-Lopez N, et al. Macrophage scavenger receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease. J Hepatol 2022; 76: 1001-12.
6.
Jiang W, Wu N, Wang X, et al. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. Sci Rep 2015; 5: 8096.
7.
Aron-Wisnewsky J, Vigliotti C, Witjes J, et al. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol 2020; 17: 279-97.
8.
Oh TG, Kim SM, Caussy C, et al. A universal gut-microbiome-derived signature predicts cirrhosis. Cell Metabolism 2020; 32: 878-88.
9.
Gill K, Bindal E, Garg P, Kumar D, Bhattacharyya R, Banerjee D. Exposure of bisphenols (BPA, BPB and BPC) in HepG2 cells results in lysosomal dysfunction and lipid accumulation. Cell Biology Int 2025; 49: 709-22.
10.
Li CL, Yao ZY, Zhang YF, et al. Bisphenols exposure and non-alcoholic fatty liver disease: from environmental trigger to molecular pathogenesis. Front Endocrinol 2025; 16. doi:10.3389/fendo.2025.1606654.
11.
Feng D, Zhang H, Jiang X, et al. Bisphenol A exposure induces gut microbiota dysbiosis and consequent activation of gut-liver axis leading to hepatic steatosis in CD-1 mice. Environ Pollut 2020; 265: 114880.
12.
Jasirwan COM, Muradi A, Hasan I, Simadibrata M, Rinaldi I. Correlation of gut Firmicutes/Bacteroidetes ratio with fibrosis and steatosis stratified by body mass index in patients with non-alcoholic fatty liver disease. Biosci Microbiota Food Health 2021; 40: 50-8.
13.
Yu JS, Youn GS, Choi J, et al. Lactobacillus lactis and Pediococcus pentosaceus-driven reprogramming of gut microbiome and metabolome ameliorates the progression of non-alcoholic fatty liver disease. Clin Transl Med 2021; 11: e634.
14.
Zhu M, Dagah OMA, Silaa BB, Lu J. Thioredoxin/glutaredoxin systems and gut microbiota in NAFLD: interplay, mechanism, and therapeutical potential. Antioxidants 2023; 12: 1680.
15.
Nowiński A, Ufnal M. Gut bacteria-derived molecules as mediators and markers in cardiovascular diseases. The role of the gut-blood barrier. Kardiol Pol 2018; 76: 320-7.
16.
Loomba R, Seguritan V, Li W, et al. Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metabol 2019; 30: 607.
17.
Yamashiro K, Kurita N, Urabe T, Hattori N. Role of the gut microbiota in stroke pathogenesis and potential therapeutic implications. Ann Nutr Metab 2021; 77 (Suppl. 2): 36-44.
18.
Li Y, Ji X, Wu H, Li X, Zhang H, Tang D. Mechanisms of traditional Chinese medicine in modulating gut microbiota metabolites-mediated lipid metabolism. J Ethnopharmacol 2021; 278: 114207.
19.
Zhang R, Gao X, Bai H, Ning K. Traditional Chinese medicine and gut microbiome: their respective and concert effects on healthcare. Front Pharmacol 2020; 11: 538.
20.
Fan JG, Kim SU, Wong VWS. New trends on obesity and NAFLD in Asia. J Hepatol 2017; 67: 862-73.
21.
Wang T, Guo XK, Xu H. Disentangling the progression of non-alcoholic fatty liver disease in the human gut microbiota. Front Microbiol 2021; 12: 728823.
22.
Chen J, Vitetta L. Gut microbiota metabolites in NAFLD pathogenesis and therapeutic implications. IJMS 2020; 21: 5214.
23.
Fang J, Yu CH, Li XJ, et al. Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications. Front Cell Infect Microbiol 2022; 12: 997018.
24.
Rom O, Liu Y, Liu Z, et al. Glycine-based treatment ameliorates NAFLD by modulating fatty acid oxidation, glutathione synthesis, and the gut microbiome. Sci Transl Med 2020; 12: eaaz2841.
25.
Shin J, Li T, Zhu L, et al. Obese individuals with and without phlegm-dampness constitution show different gut microbial composition associated with risk of metabolic disorders. Front Cell Infect Microbiol 2022; 12: 859708.
26.
Li L, Li T, Liang X, et al. A decrease in Flavonifractor plautii and its product, phytosphingosine, predisposes individuals with phlegm-dampness constitution to metabolic disorders. Cell Discov 2025; 11: 25.
27.
Pan Y, Guo J, Hu N, et al. Distinct common signatures of gut microbiota associated with damp-heat syndrome in patients with different chronic liver diseases. Front Pharmacol 2022; 13. doi:10.3389/fphar.2022.1027628.
28.
Zhang F, Wu J, Ruan H, et al. ZeXie decoction alleviates non-alcoholic fatty liver disease in rats: the study of genes, lipids, and gut microbiotas. Biochem Biophys Res Commun 2022; 632: 129-38.
29.
Zhao H, Zong Y, Li W, et al. Damp-heat constitution influences gut microbiota and urine metabolism of Chinese infants. Heliyon 2023; 9: e12424.
30.
Chen X, Tan F, Zhang H, et al. Serum cytokine profiles in phlegm-dampness constitution and damp-heat constitution using proteomic antibody microarray. Eur J Integr Med 2022; 52: 102126.
31.
Nakagawa H, Saio T, Nagao M, et al. Conformational dynamics of a multidomain protein by neutron scattering and computational analysis. Biophys J 2021; 120: 3341-54.
32.
Rabe M, Toparli C, Chen YH, Kasian O, Mayrhofer KJJ, Erbe A. Alkaline manganese electrochemistry studied byin situandoperandospectroscopic methods – metal dissolution, oxide formation and oxygen evolution. Phys Chem Chem Phys 2019; 21: 10457-69.
33.
Smalley CM, Fertel BS, McShane AJ, Cremer PC, Muir MR, Mentias A. Outcomes in emergency department patients with intermediate elevations in high-sensitive cardiac troponin T. Am J Emerg Med 2023; 65: 212-3.
34.
Shen S, Zhong H, Zhou X, et al. Advances in traditional chinese medicine research in diabetic kidney disease treatment. Pharm Biol 2024; 62: 222-32.
35.
Kumar D, Behal S, Bhattacharyya R, Banerjee D. Pseudoesterase activity of albumin: a probable determinant of cholesterol biosynthesis. Med Hypoth 2018; 115: 42-5.
36.
Wang S, Lin X, Zhu C, et al. Association between nonalcoholic fatty liver disease and increased glucose-to-albumin ratio in adults without diabetes. Front Endocrinol 2024; 14: 1287916.
Share
RELATED ARTICLE
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
